Roundtables
Managing capital through the fog of Solvency II
Delays and doubts about Solvency II implementation have created fresh challenges for insurers in managing their capital. In part one of this InsuranceERM/Towers Watson roundtable, participants discussed how it can be an opportunity to do things better
Coping with competing views on capital setting
In the second part of the InsuranceERM/Towers Watson roundtable on capital management, participants discussed the impact of ICAS+, the Prudential Regulation Authority's view on internal models and the importance of rating agencies
Coping with the Solvency II delay
Insurers rue Solvency II's loss of momentum
Leaving aside the further setbacks to the timetable for Solvency II implementation, participants in the recent InsuranceERM/QlikView roundtable also expressed concern over the attitude of regulators to internal models and the likelihood that the industry would see no capital benefits from complying with the directive
Own Risk and Solvency Assessment
Is the ORSA the biggest challenge of Solvency II?
The frequency of the ORSA, its forward-looking nature, potential discrepancies between it and the SCR "" all these issues were discussed at an InsuranceERM/SAS roundtable where there was general agreement that, despite some key uncertainties, the ORSA is a valuable exercise
Weighing up the costs and benefits of the ORSA
Part two of last month's InsuranceERM/SAS roundtable on the own risk and solvency assessment (ORSA) focused on dry runs, keeping the ORSA up-to-date, the management/board role, data/technology and the value or otherwise of the whole exercise
The challenges of Solvency II
Extracting value from Solvency II: a roundtable discussion
The benefits vs the costs, risk appetite, the ORSA, strategic opportunities, diversification benefits. These were just some of the points covered by a group of risk and Solvency II experts during a lively discussion hosted by Deloitte and InsuranceERM
The challenges of Solvency II: a roundtable discussion
Data, the moving regulatory timetable, the IMAP, equivalence with the US and the lack of certainty on key points in the directive are among the challenges faced by re/insurers preparing for Solvency II. Plenty of food for thought and discussion at the roundtable of risk and Solvency II experts hosted by Deloitte and InsuranceERM
Preparing for Solvency II
Solvency II roundtable: how to use the "extra" year
Is the delay in full implementation of Solvency II a boon or a bugbear? What are the implications for the regulators, as well as the regulated? CROs and Solvency II experts debated these and other issues last month in an InsuranceERM roundtable, sponsored by SAS
Solvency II roundtable: embedding processes and live testing are benefits of "extra" year
Priming the board, the use test, the ORSA, "walking" the regulators through insurers' business and processes - these are some of the benefits of the delay in full implementation of Solvency II cited by the CROs and Solvency II experts who debated these issues in an InsuranceERM roundtable, sponsored by SAS